Athlete doping confrontation efficacy and confrontation likelihood

Evidence supports the role of coach doping confrontation efficacy (DCE; Sullivan et al., 2015) as a deterrent against athletes’ doping cognitions (Boardley et al., 2019; Sullivan & Razavi, 2017), but the role of the athlete has largely been ignored. Current anti-doping campaigns encourage athletes to report doping misconduct (i.e., whistleblowing), but some athletes would prefer to confront the athlete directly (Erickson et al., 2017). Thus, it is important to consider what may contribute to athletes’ likelihood to confront a doping teammate or opponent. The purpose of this study was to determine whether DCE could predict an athlete’s likelihood to confront a doping teammate or opponent. Additionally, doping moral disengagement (MD) was included as a possible moderator of this relationship. Surveys were completed by 155 college athletes (n_male = 145) to measure their perceived DCE, doping MD, likelihood to confront a teammate, and likelihood to confront an opponent. Separate linear regression analyses were run for the two targets of confrontation. In the teammate model, both DCE and doping MD were significant predictors of confrontation likelihood. DCE was the only significant predictor in the opponent model. Neither model presented with a significant interaction, suggesting no moderation effect. Results suggest perceived DCE is associated with a greater likelihood to confront a doping athlete, regardless of whether they are a teammate or opponent; however, moral disengagement plays a greater role if the athlete is a teammate. These findings imply that confrontation may be the first line of defense against doping before whistleblowing action is taken. Research should continue to explore antecedents and consequences of athlete doping confrontation, providing greater insight into the whistleblowing process.     

Behavior of neonates exposed in utero to methadone as assessed on the Brazelton scale

Twenty-nine infants exposed in utero to methadone and 37 comparison infants were examined on the Neonatal Behavioral Assessment Scale at early and late neonatal ages. All infants were full-term at birth, over 2500 g, and not yet circumcised at the early assessment. None of the methadone-exposed infants were breast-fed or were being treated pharmacologically for withdrawal. During the first week of life, methadone-exposed neonates differed from comparison ones in motoric behavior. Relative to comparison-group infants, they were jerkier and more tremulous, tense, active, and better able to put hand in mouth. By the end of the first month these differences diminished, although there was still a tendency for the methadone-exposed infants to have elevated body tonus. Neither perinatal complications, birth weight, nor sex of infant could explain the early neonatal differences between the methadone and comparison groups. Past the early stage of acute withdrawal, neonates exposed prenatally to methadone behave not unlike their nonexposed peers.     

FDA儿童药物临床试验规范化对我国的启示

对美国食品药品监督管理局（Food and Drug Administration,FDA）儿童药物临床试验的规范化进行界定,发现我国面临儿童用药方面存在安全隐患、儿童药物临床试验存在需求缺口、儿童药物临床试验审查不够规范等现实困境,引发规范儿童药物临床试验的关键性思考。借鉴FDA对儿童药物临床试验的规范化实践,总结FDA儿童药物临床试验相关法案、临床试验指南文件以及对伦理审查委员会的监管措施,得出完善儿童药物临床试验专门法规和指南、加强相关伦理委员会监管和指导、规范儿童药物临床试验伦理审查、加大儿童受试者保护力度等对我国的启示。

     

Children's Representations of the World of Drugs

The changing profile of drug use has highlighted the need for age-appropriate education which requires insight into children's representations of drugs. Representations were elicited from 134 children aged between 5 and 11 years, drawn from two schools, by asking them to draw and write their responses to questions relating to a story about losing and finding a bag of drugs. Relevant responses were generated by 119 children aged between 8 and 11 years. A content analysis of these responses revealed differences with school and age. Older children were more likely to recognize that drugs can be good or bad depending on type, quantity taken and reason for use. The children had firm ideas about who takes drugs and their motivations and were knowledgeable about methods of use. They recognized that drugs can be dangerous, but had little understanding of how or why. The children's representations were characterized by fear and uncertainty and most wanted to know more. These findings are used to argue that there is a need for child-centred constructivist approaches to drug education which seek to demystify drugs and drug use and to orientate children to the realities of the world of drugs in the 1990s.     

中西医结合若干问题的比较思考

讨论中西医结合对西医临床思维的影响。对于慢性病中医注意病人的主观症状,与病人就医的缘由一致;西医重视客观的功能和结构异常,其判断结果有时未必能被病人接受。近年来西医开始重视病人的生活质量,其实中医的辨证指标有很多就是针对病人的生活质量。中医的整体观念同样体现在急性感染的治疗中,现代研究显示,清热解毒法除祛邪外也兼顾扶正。中西医结合促进了中西药合用,但须注意合理应用,避免合用的不良效果。     

现代复苏的药物应用现状的理性思考

回顾了复苏药物应用研究的现状,运用创新思维的科学方法对现代复苏药物临床应用研究中的医学和伦理难题进行了理性分析,阐明了理论,逻辑思维,哲学思考对临床实践和医学研究的重要性。     

The Burden of Dementia: A Medical and Research Perspective

Alzheimer's disease remains the most common form of dementia. Dementia symptoms vary depending on individual personality, life experience, and social and cultural influences. As dementia progresses, involvement of multi-disciplinary health care professionals is needed to manage the disease. Alzheimer research is progressing rapidly. While 5% of all Alzheimer's disease may be genetically determined, the majority is not. Susceptibility genes can reveal the risk of contracting Alzheimer's disease. Early life risk factors such as education, nutrition, and vascular disease may increase the likelihood of dementia in later life. In the United States, two acetylcholinesterase inhibitors have been approved as cognitive enhancers. Possible prevention and symptomatic treatment interventions have focused on estrogen replacement therapy, antioxidants, and anti-inflammatory medications. Research advances have improved the clinical management of dementia. Ethical implications to the patient, family, and society are multiple and remain challenging.     

应用分子靶向治疗的时机选择

分子靶向药物的出现显示出肿瘤治疗传统模式的重要进展。与传统放疗、化疗相比,分子靶向治疗因其特异性高、不良反应轻微,在恶性肿瘤个体化治疗中扮演重要角色。十五年来,分子靶向药物的出现,给肿瘤的治疗模式带来重大改变,也给临床医生带来新的挑战。准确把握分子靶向药物应用时机,获得最大临床效果,已成为肿瘤治疗领域关注热点。本文就非小细胞肺癌、消化系统肿瘤、乳腺癌、肾癌治疗中分子靶向药物如何选择应用时机进行阐述。     

Psychometric Properties of the Locus of Control of Behaviour Scale (LCBS) among Australians Seeking Alcohol and Other Drug (AOD) Treatment

Despite a paucity of studies evaluating the psychometric properties of the Locus of Control of Behaviour Scale (LCBS), it continues to be widely used in behavioural research. The present study sought to redress this gap in the literature. The 17‐item LCBS was administered to 373 Australians attending Alcohol and Other Drug (AOD) treatment agencies in the northern metropolitan region of Perth. Confirmatory factor analyses were conducted in order to determine which of several plausible measurement models provided the best fit for the data. A unidimensional model, recommended by the authors of the LCBS, and a two‐dimensional (Internal Locus of Control vs External Locus of Control) model provided poor fits. Other multidimensional models, differing only in the dimensionality of the externality factor, were also tested. A multidimensional model consisting of an Internal Locus of Control factor and four component External Locus of Control factors provided the best fit; however, the fit is probably best described as “reasonable” rather than “good.” A subsequent exploratory factor analysis using parallel analysis indicated a cohesive internality factor; however, the externality factor showed a tendency to fragment into smaller components. Results were discussed in terms of the problematic externality factor.